{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Forster RB"],"funding":["Kreftforeningen"],"pagination":["1109-1119"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9544783"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["151(7)"],"pubmed_abstract":["Studies have suggested that prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT) are at increased risk of developing or exacerbating cardiovascular disease (CVD). We aimed to explore the association between ADT for PCa and subsequent CVD and all-cause mortality in this nationwide, longitudinal study. We also evaluated the role of cardiovascular risk and ADT duration to determine effect modification. Norwegian registry data were used to identify patients with PCa from 2008-18 and who received primary ADT in the first year after diagnosis. The associations between ADT and composite cardiovascular events, and the individual components of myocardial infarction, stroke and heart failure, in addition to atrial fibrillation and all-cause mortality, were explored using time-"],"journal":["International journal of cancer"],"pubmed_title":["Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer."],"pmcid":["PMC9544783"],"funding_grant_id":["182360‐2016","08154‐2019"],"pubmed_authors":["Forster RB","Engeland A","Kvale R","Hjellvik V","Bjorge T"],"additional_accession":[]},"is_claimable":false,"name":"Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.","description":"Studies have suggested that prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT) are at increased risk of developing or exacerbating cardiovascular disease (CVD). We aimed to explore the association between ADT for PCa and subsequent CVD and all-cause mortality in this nationwide, longitudinal study. We also evaluated the role of cardiovascular risk and ADT duration to determine effect modification. Norwegian registry data were used to identify patients with PCa from 2008-18 and who received primary ADT in the first year after diagnosis. The associations between ADT and composite cardiovascular events, and the individual components of myocardial infarction, stroke and heart failure, in addition to atrial fibrillation and all-cause mortality, were explored using time-","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-04T20:09:48.345Z","creation":"2025-04-04T20:09:48.345Z"},"accession":"S-EPMC9544783","cross_references":{"pubmed":["35489025"],"doi":["10.1002/ijc.34058"]}}